References
- Kwaan HC, Soff GA Management of thrombotic thrombo-cytopenic purpura and hemolytic uremic syndrome. Semin. Hematol. 1997; 34: 159–166.
- Ruggementi P, Remuzzi G Pathophysiology and manage-ment of thrombotic microangiopathies. J. Nephrol. 1998; 11: 300–310.
- Anroli SP. The pathophysiology of hemolytic uremic synd-rome. Curr. Opin. Nephrol. Hypertens. 1999; 459–464.
- Rock G, Shumak K, Bushard N, et al. Comparison of plasma exchange with plasma infusion in the therapy of thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1991; 325: 393–397.
- Bell WR, Braine HG, Ness PN, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N. Engl. J. Med. 1991; 325: 398–403.
- Wada H, Ohiwa M, Kineko T, et al. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombo-cytopenic purpura and disseminated intravascular coagu-lation. Am. J. Hematol. 1992; 39: 20–24.
- Wada H, Mori Y, Shimura M, et al. Poor outcome in dis-seminated intravascular coagulation or thrombotic throm-bocytopenic purpura with severe vascular endothelial injury. Am. J. Hematol. 1998; 58: 189–194.
- Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1998; 339: 1585–1594.
- Musio F, Bohen EM, Yuan CM, Welch PG. Review of throm-botic thrombocytopenic purpura in the setting of systemic lupus erythemetosis. Semin. Arthritis Rheum.1998; 28: 1–19.
- Schriber JR, Herzig GP. Transplantation associated throm-botic thrombocytopenic purpura and hemolytic uremic syn-drome. Semin. Hematol. 1997; 34: 126–133.
- Leavey SF, Weinberg J. Thrombotic thrombocytopenia associated with tidopidine therapy. J. Am. Soc. Nephrol. 1997; 8: 689–693.
- Price SK, Thall PF, Kish SK, et al. Prognostic indicators for blood and marrow transplant patients admitted to an inten-sive care unit. Am. J. Resp. Crit. Care Med. 1998; 158: 876–874.
- Huaringa AJ, Leyva FJ, Giralt SA, et al. Outcome of bone marrow transplantation patients requiring mechanical ven-tilation. Crit. Care Med. 2000; 28: 1014–1017.
- Shorr AF, Moores LK, Edenfield WJ, et al. Mechanical ven-tilation in hematopoietic stem cell transplantation: can we effectively predict outcomes. Chest 1999; 116: 1012–1018.
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit. Care Med. 1985; 13: 818–829.
- Marshall JC, Cook DJ, Christou, Bernard GR, Sprung CL, et al. Multiple organ dysfunction score: reliable descriptor of complex clinical outcome. Crit. Care Med. 1995; 23: 1638–1652.
- Rose M, Eldor A. High incidence of relapses in thrombotic thrombocytopenic purpura: a clinical study of 38 patients. Am. J. Med. 1987; 83: 437–444.
- Knobl P, Rintelen C, Koniek G, et al. Plasma exchange treat-ment of thrombotic thrombocytopenic purpura in critically ill patients. Inten. Care Med. 1997; 23: 44–50.
- Douzinas EE, Markakis K, Karabinia A, et al. Early plasma-pheresis in patients with thrombotic thrombocytopenic purpura. Crit. Care Med. 1992; 20: 57–61.
- Glance LG, Osler T, Shinozaki T. Effect of varying the case mix on the standardized mortality ratio and the W statistic. Chest 2000; 117: 1112–1117.